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of surgical groups to consider in situ replacement as an
alternative treatment option.1-11 Excision of the infected
graft with immediate in situ graft replacement is appealing
because it avoids the need for an extra-anatomic bypass
graft, and the additional physiologic stress and potential
morbidity associated with staged or multiple procedures.
In the treatment of extracavitary graft infections, anatomic
routes to bypass the infected prosthesis may not be avail-
able, requiring either in situ replacement or amputation.
Several developments have fostered the expanded applica-
tion in situ replacement, including (1) the realization that
many late-appearing graft infections are the result of a
Staphylococcus epidermidis, a bacterium that produces a
low-grade biofilm infection amenable to either autog-
enous vein or prosthetic replacement, (2) the successful
use of lower-limb deep veins (superficial femoral-popliteal
vein [SFPV]) or cryopreserved arterial homografts as
bypass conduits in the beds of excised infected prosthetic
grafts, and (3) the development of antibiotic-bonded
prosthetic grafts.7-17 Although staging of extra-anatomic
bypass grafting before removal of an infected aortic graft
Conventional management of an infected vascular
prosthesis has emphasized an aggressive approach that
includes culture-specific antibiotic administration, total
graft excision combined with adjacent native artery
debridement, and if collateral circulation is inadequate, ex
situ bypass grafting. For infrarenal aortic graft infections,
this approach has been associated with significant periop-
erative mortality (12%-27%) and morbidity (amputation,
10%-15%; artery disruption, 5%-10%; ex situ graft throm-
bosis/infection, 10%-24%) rates, and prompted a number
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Purpose: The purpose of this study was to analyze the outcome of an individualized treatment algorithm for prosthetic
graft infection, including the application of in situ graft replacement, based on clinical presentation, extent of graft
infection, and microbiology.
Methods: There was a retrospective review (1991-2000) of 119 patients with 68 aortoiliofemoral or 51 extracavitary
(infrainguinal, 19; axillofemoral, 16; femorofemoral, 16) prosthetic graft infections presenting more than 3 months
(range, 3-136 months) after implantation/revision. The treatment algorithm consisted of graft excision with or with-
out ex situ bypass grafts for patients presenting with sepsis or graft-enteric erosion, whereas in situ replacement (autog-
enous vein, rifampin-bonded polyester, polytetrafluoroethylene [PTFE]) was used in patients with less virulent
gram-positive graft infection, in particular infections caused by Staphylococcus epidermidis. Outcomes (death, limb loss,
recurrent infection) were correlated with treatment type and infecting organism.
Results: In situ replacement was used in 52% of aortoiliofemoral (autogenous vein, 10; rifampin-bonded polyester, 6;
PTFE, 9) and 80% of extracavitary (autogenous vein, 26; PTFE, 9; rifampin, 6) graft infections. Total graft excision
with ex situ bypass was performed in 34 patients, including 21 patients with graft-enteric erosion/fistula, with a 21%
operative mortality and 9% amputation rate. In situ graft replacement was used to treat 76 graft infections with a 30-
day operative mortality rate of 4% and an amputation rate of 2%. Graft excision alone was performed in nine patients
with one 30-day death. Gram-positive cocci were the prevalent infecting organisms of both intracavitary (59% of iso-
lates) and extracavitary (76% of isolates) graft infections. S epidermidis was the infecting organism in 40% of patients,
accounting for the expanded application of in situ prosthetic replacement using a rifampin-bonded polyester or PTFE
prosthesis. During the mean follow-up interval of 26 months, recurrent graft infection developed in 3% (1 of 34) of
patients after conventional treatment, 3% (1 of 36) patients after in situ vein replacement, and 10% (4 of 40) patients
after in situ prosthetic graft replacement (P > .05). Failure of in situ replacement procedures was the result of virulent
and antibiotic-resistant bacterial strains. 
Conclusions: In situ replacement was a safe and durable option in most (64%) patients presenting with prosthetic graft
infection. In situ replacement with a rifampin-bonded graft was effective for S epidermidis graft infection, but when
the entire prosthesis is involved with either a biofilm or invasive perigraft infection, in situ autogenous vein replace-
ment is preferred. Virulent graft infections presenting with sepsis, anastomotic dehiscence, or graft enteric fistula
should continue to be treated with total graft excision, and if feasible, staged ex situ bypass graft. (J Vasc Surg
2001;34:411-20.)
has reduced overall morbidity associated with the treat-
ment of an aortic graft infection, proponents of in situ
replacement therapy have reported a lower mortality and
amputation rate in similar patient populations.2,6,8,10,11
Most vascular groups use a singular approach toward
the treatment of prosthetic graft infections, especially aor-
toiliac-femoral infections (ie, conventional management or
in situ replacement). On the basis of our experimental and
clinical research on S epidermidis graft infections, our vas-
cular division evolved to a patient-specific treatment algo-
rithm for both intracavitary and extracavitary graft
infections.7,13-16 We have used both conventional and in
situ replacement management to treat an infected vascular
prosthesis based on clinical presenting signs, extent of
graft involvement, and the microbiology of the infectious
process. For low-grade graft infections caused by staphy-
lococci, in situ prosthetic (segmental S epidermidis infec-
tions), or vein (entire graft infected by S epidermidis or
Staphylococcus aureus), replacement is the preferred
approach, whereas for patients with aortic graft infections
complicated by sepsis or graft-enteric erosion/fistula, pre-
liminary axillofemoral bypass graft followed by total graft
excision has remained our standard treatment. More
recently, we have used an antibiotic (rifampin)–bonded
graft as the preferred replacement conduit in treating S
epidermidis biofilm graft infections.17 The purpose of this
report was to analyze outcomes after application of this
individualized treatment to patients presenting with late-
appearing (> 3 months after implantation) prosthetic graft
infections. This patient cohort was selected because several
treatment options are possible, in contrast to the treat-
ment of early postoperative graft infection, which in our
experience is a less common occurrence and primarily
involves the management of a postoperative wound infec-
tion or exposed graft. A 10-year experience treating 119
consecutive patients was reviewed to assess patient-specific
management with an expanded application of both in situ
prosthetic and vein replacement treatment for treatment
of intracavitary (aortoiliofemoral) and extracavitary pros-
thetic graft infections.
CLINICAL MATERIAL AND METHODS OF
STUDY
Patients. Between 1991 and 2000, 119 patients (82
men, 37 women) having a mean age of 69 ± 8 years (range,
46-84 years) were referred to the Division of Vascular
Surgery with a proven or suspected diagnosis of an aortoil-
iofemoral (n = 68) or extracavitary (n = 51; including
infrainguinal, 19; axillofemoral, 16; femorofemoral, 16)
prosthetic graft infections. Although all patients were
beyond 3 months from graft implantation or revision, 24
patients had undergone recent incision and drainage pro-
cedures to treat perigraft infection presenting in the groin,
in the thigh, or along an axillofemoral graft. Patient and
outcome data were obtained by review of our vascular reg-
istry and archived referring physician, hospital, and outpa-
tient clinic records. Study end points were death, limb loss,
recurrent graft infection, and secondary procedures related
to the treatment of graft infection during the follow-up
period that extended to December 2000. 
Initial aortoiliofemoral bypass grafting was prompted by
aneurysmal and occlusive disease in similar frequency,
whereas 96% of the extracavitary grafts were implanted to
treat symptomatic atherosclerotic occlusive disease (Table I).
All but four infected aortic grafts were constructed of poly-
ester, and 53 (78%) of 68 were in an aortofemoral bypass
configuration. Extracavitary graft infections primarily
involved a polytetrafluoroethylene (PTFE) conduit (88%). 
The postoperative time interval and mode of presenta-
tion of aortoiliofemoral (intracavitary) and extracavitary
graft infections differed (Table II). Intracavitary graft
infections presented an average of 35 months later than
extracavitary peripheral graft infections and were more
commonly associated with gastrointestinal bleeding and
false aneurysm. The most common presentation of an
aortofemoral graft infection was a patient without a fever
and with a sinus tract or inflammatory mass contiguous
with the prosthetic graft in the femoral or groin region.
Obvious signs of graft infection (fever, purulent wounds)
were common presenting signs of extracavitary graft infec-
tions. Sepsis or blood cultures positive for bacteria were
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Table I. Indication, location, and graft material of 119 prosthetic graft infections
Aortoiliofemoral (%) Extracavitary (%)
No. 68 (58) 51 (42)
Indication
Aneurysmal disease 41 (59) 2 (4)
Occlusive disease 25 (37) 49 (96)
Trauma 2 (4) —
Graft location
Aortoiliac 12 (16) Axillofemoral 16 (31)
Aortofemoral 53 (79) Femorofemoral 16 (31)
Iliofemoral 3 (5) Infrainguinal 19 (38)
Graft material
Polyester 64 (94) 6 (12)
PTFE 4 (6) 45 (88)
uncommon, occurring in only five patients with isolates of
S aureus (n = 3), Klebsiella pneumoniae (n = 1), or
Pseudomonas aeruginosa (n = 1).
Diagnostic evaluation. Patient evaluation was indi-
vidualized according to graft type, presenting signs, and
symptoms. Patients with aortic graft infections underwent
computed tomography (CT) scanning of the abdomen,
pelvis, and, if appropriate, the femoral regions so that the
extent of graft infection could be identified and other pos-
sible infection-related (false aneurysm, perigraft air, 
or hydronephrosis) complications could be identified. All
patients treated for graft-enteric erosion had abnormalities
revealed on CT scanning. Upper endoscopy performed 
in 18 of 21 patients with suspected graft erosion into 
the gastrointestinal tract visualized graft material in the
duodenum in only two patients. In 24 patients with
inflammatory groin masses or perigraft abscesses, wound
exploration in the operating room was performed as an
initial procedure to drain a septic focus or obtain microbi-
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ologic samples to isolate the infecting organism(s). CT-
guided aspiration of perigraft fluid was used in only four
patients with subsequently proven S epidermidis aorto-
femoral graft biofilm infections. All stable patients under-
went arteriography to aid in planning the subsequent graft
excision and reconstructive procedure.
Treatment algorithm. Patients were managed with
several methods (Table III), including graft excision alone,
conventional treatment (ex situ bypass and total graft exci-
sion), or in situ replacement of the infected prosthesis with
either autogenous vein (greater saphenous, upper extrem-
ity, lower-limb superficial femoral vein [SFV]) or pros-
thetic conduit (PTFE, rifampin-soaked gelatin-sealed
polyester). If the infected graft could be excised because of
adequate collateral circulation or acute thrombosis, this
option was selected. Total graft excision coupled with
axillofemoral bypass graft (with externally supported
ringed PTFE) was selected for patients with aortoiliac
graft infections presenting with graft enteric erosion/fis-
Table II. Time from graft implantation and presenting signs (expressed as % of patients) of 68 aortoiliac-femoral and
51 extracavitary (axillofemoral, femorofemoral, infrainguinal) prosthetic graft infections
Aortoiliofemoral Extracavitary P value
Time interval (mo) from graft implantation/revision (range) 42 ± 28 (3-142) 7 ± 4 (3-18) < .001
Presenting signs
Sepsis 10% 8%
Gastrointestinal bleeding 33% —
Fever 36% 57%
Groin sinus 18% 10%
Groin mass 20% 8%
Purulent wound 8% 65% < .001
False aneurysm 28% 5% < .01
Hydronephrosis 15% —
Septic emboli 0% 2%
Graft thrombosis 2% 8%
Table III. Criteria used for patient-specific treatment of a prosthetic graft infection based on presenting signs, extent
of graft involvement, and microbiology of the infectious process
Treatment option Presenting signs Microbiology
Graft excision Graft thrombosis, viable limb after Any organism
graft excision (adequate collaterals)
Total excision 
With preliminary ex situ bypass graft Graft-enteric erosion in stable patient or Any organism
aortofemoral or intracavitary graft infection 
associated with sepsis or 
bilateral hydronephrosis*
With simultaneous ex situ bypass graft Graft-enteric fistula in unstable patient Any organism
In situ replacement
Autologous vein Invasive perigraft infection without Any organism
sepsis or anastomotic hemorrhage
Antibiotic-bonded prosthetic Total† or segmental graft involvement S epidermidis/S aureus
biofilm infection‡
*Signs of extensive retroperitoneal infection/inflammation.
†Total graft replacement for a biofilm infection limited to axillofemoral bypasses or aortofemoral graft infections in patients not candidates for deep vein
replacement because of vein availability or multiple comorbidities. 
‡No organisms identified on Gram stain of perigraft exudate/fluid. 
tula, sepsis, or bilateral hydronephrosis (indicating exten-
sive retroperitoneal inflammation and diffuse graft infec-
tion). In situ replacement with autologous vein was
performed when patients with invasive perigraft infections
(intracavitary or extracavitary) were identified by preoper-
ative culture positive for S aureus, S epidermidis (total graft
involvement), or gram-negative bacteria, and when intra-
operative Gram stain of perigraft fluid demonstrated bac-
teria. Preoperative venous mapping was performed in all
patients in whom in situ autogenous venous reconstruc-
tion was considered an option. Deep, lower-limb vein
(superficial femoral popliteal [SFP]) reconstruction of the
aortic iliac segment for aortofemoral graft infection or
femoral-femoral graft infections was performed with the
technique described by Clagett et al.8 In situ prosthetic
(PTFE, rifampin-soaked, gelatin-impregnated polyester)
replacement was performed in patients with documented
biofilm graft infections (ie, afebrile, negative intraoperative
Gram stain, sterile preoperative perigraft culture).
Diagnostic criteria for biofilm graft infections and the
technique of in situ prosthetic graft replacement have not
changed from prior reports.7,15 Rifampin bonding of a
gelatin-sealed polyester graft (Gelsoft; Vascutek Ltd,
Glasgow, UK) was performed by soaking the graft at room
temperature in a rifampin solution of 60 mg/mL (Rifadin;
Merrill Dow Pharmaceutical, Kansas City, Mo) for 15
minutes.16,17
Microbiologic recovery techniques. At the time of
graft excision, Gram stain of perigraft fluid was performed
and swab cultures placed in transport media and cultured
for aerobic and anaerobic bacteria. Explanted graft speci-
mens were cultured in tryptic soy broth to enhance the
recovery of microorganisms, including coagulase-negative
staphylococci.
Antibiotic administration. All patients received par-
enteral broad-spectrum antibiotics before graft excision. In
patients with known or suspected biofilm graft infections,
vancomycin was administered for at least 3 days before in
situ replacement treatment. All patients received parenteral
culture–specific antibiotic for 4 to 6 weeks after treatment.
After in situ prosthetic replacement, oral antibiotics were
continued for an additional 6 weeks to 2 months.
Follow-up. Patients were evaluated in the Vascular
Surgery Clinic at 3- to 6-month intervals by means of clin-
ical examination and duplex ultrasonography for signs of
graft infection, false aneurysm, or development of graft
stenosis. Patients treated for an aortic graft infection were
evaluated with serial CT scans initially at 3- to 6-month
intervals; if the scan results were normal, then patients
were evaluated at yearly intervals. Six patients were lost to
follow-up after 1 year, 4 patients after 2 years, and 5
patients after 4 years. No patient treated with prosthetic
replacement was lost to follow-up. 
Data analysis. Statistical comparisons were made
with the χ2 test with a P value less than .05 considered sig-
nificant. Cumulative survival for the study groups was cal-
culated by means of the Kaplan-Meier method.
RESULTS
Microbiology. Bacteria isolates recovered from
explanted infected graft segments are listed in Table IV.
S epidermidis was the most common–infecting organism
isolated from 44 (37%) of 118 explanted grafts (aortoil-
iofemoral, 49%; extracavitary, 22%). No microorgan-
isms were isolated from two infected aortic grafts and
three extracavitary grafts despite clinical signs of an 
S epidermidis biofilm graft infection. S aureus was iso-
lated from 40 patients and included 11 (27%) methi-
cillin-resistant S aureus (MRSA) strains. Gram-negative
bacteria or Enterococcus strains were isolated from 31
(46%) of 68 aortoiliofemoral, and 10 (20%) of 51 extra-
cavitary grafts. Escherichia coli and P aeruginosa were
the two most common gram-negative bacteria strains
isolated. Candida species was recovered from two
infected aortic grafts with clinical signs of a biofilm
graft infection.
Surgical outcomes. In situ replacement was used in
52% of aortoiliofemoral and 80% of extracavitary pros-
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Table IV. Intraoperative culture results from 119 patients with 68 aortoiliofemoral and 51 extracavitary graft infec-
tions
Type of graft
Microorganism isolated Aortoiliofemoral grafts Extracavitary Total (%)
No growth 2 3 5 (4)
Streptococcus 0 1 1 (<1)
Staphylococcus
S aureus 13 27 40 (31)
S epidermidis 33 11 44 (34)
Gram-negative rods
E coli 18 2 20 (15)
Pseudomonas species 6 5 11 (8)
K pneumoniae 2 1 3 (2)
Enterococcus 5 2 7 (5)
Candida species 2 0 2 (2)
79 isolates 49 isolates 128 isolates
thetic graft infections (Figs 1 and 2). In situ replacement
with a “new” prosthetic (rifampin-bonded [16], PTFE
[9]) graft (25 [37%] of 68) was used more frequently than
autogenous vein (saphenous/upper limb [3]; SFPV [7])
reconstruction (10 [15%] of 68) for intracavitary, aortoil-
iofemoral graft infections. The entire aortic prosthesis 
was explanted in only two of 25 aortofemoral graft infec-
tions treated with in situ prosthetic replacement. A biofilm
graft infection, documented in approximately 40% of
patients by a negative intraoperative Gram stain but posi-
tive culture for either S epidermidis or Candida species,
accounted for the expanded application of in situ pros-
thetic replacement and was associated with a 5% (2 of 40
patients) 30-day mortality rate and zero amputation rate
(Table V). In several patients, autogenous venous recon-
struction was used to treat a biofilm infection because of
diffuse graft involvement.
The most common procedure used to treat an aortic
graft infection was a staged ex situ bypass graft followed by
total graft excision, which was performed in 31 (45%)
patients, including 21 patients with a graft-enteric erosion
(n = 17) or fistula (n = 4). Conventional management of
intracavitary aortic graft infection was associated with a
21% (7 of 34 patients) 30-day mortality rate and an over-
all 9% amputation rate, but there was a 5% (1 of 24
patients) incidence of limb loss in survivors (Table V).
Graft excision alone was performed in nine patients with
one (11%) death, a 75-year-old man who presented with
sepsis and hemorrhage caused by a Pseudomonas infection
of a femoropopliteal PTFE bypass graft. Overall, the oper-
ative mortality rate was increased (P < .02) in patients
treated for an intracavitary (15% [10 of 68]) compared
with an extracavitary (2% [1 of 51]) prosthetic graft infec-
tion. More than half (6 of 11) of the 30-day operative
deaths in this series occurred in patients with secondary
aortoenteric fistula/erosion.
Autogenous vein reconstruction was used to treat 10
(15%) of 68 aortic graft infections and 26 (51%) of 51
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extracavitary graft infections. Overall, the mortality rate of
in situ autogenous venous reconstruction was 6% (2 of 36
patients), and one (3%) below-knee amputation occurred
in this treatment group. In seven patients with diffuse
aortofemoral graft infection, SFPV reconstruction was
used to replace the aortoiliac segment after total graft exci-
sion. Seven patients with femorofemoral graft infection
underwent total graft excision and SFPV replacement.
Two patients died after deep vein SFP in situ reconstruc-
tion of persistent MRSA infection; anastomotic rupture
occurred in one patient. In the treatment of extracavitary
prosthetic graft infections, autogenous vein replacement
was the most common procedure (26 [51%] of 51) per-
formed and the only option used in the 19 patients with
infrainguinal PTFE graft infection. In general, perigraft
abscesses were incised and drained, and graft replacement
was performed after several days of culture-specific antibi-
otic administration. In situ prosthetic replacement for
extracavitary graft infection used in 15 (29%) of 51
patients was limited to the treatment of low-grade
axillofemoral (n = 11) or femoral-femoral (n = 8) extra-
cavitary graft infections.
In 22 patients a rifampin-bonded graft was used to
treat low-grade prosthetic graft infection involving single
(n = 16) or bilateral (n = 2) aortofemoral graft limbs,
femoral-femoral graft (n = 3), or an axillofemoral graft (n
= 1). Sartorius muscle flap coverage of the in situ replace-
ment graft in the groin was performed in 15 (68%)
patients. One patient died after anastomotic rupture of an
SFV reconstruction performed to treat MRSA infection of
the replaced rifampin-bonded graft. No amputations
occurred early or late in the rifampin-bonded graft treat-
ment group (mean follow-up of 18 ± 9 months). 
During a mean follow-up interval of 26 months
(range, 3 to 96 months), 18 patients (graft excision alone,
1 of 8 survivors; graft excision plus ex situ bypass graft, 4
Fig 1. Surgical treatment used for 66 aortic and two iliofemoral
prosthetic graft infections. PTFE, Polytetrafluoroethylene; SFP,
superficial femoral popliteal; UE, upper extremity.
Fig 2. Surgical treatment used for 51 extracavitary (infrainguinal
[19], axillofemoral [16], femorofemoral [16]) prosthetic graft
infections. PTFE, Polytetrafluoroethylene; SFA, superficial
femoral artery; SFP, superficial femoral popliteal; UE, upper
extremity.
of 27; rifampin-bonded replacement, 5 of 21; PTFE
replacement, 2 of 18; autogenous vein reconstruction, 6
of 34) died at intervals ranging from 5 to 80 months after
treatment. Two late deaths were related to treatment for
recurrent graft infection. Patient survival, including peri-
operative deaths, was 89% at 6 months, 82% at 2 years, and
70% at 4 years. Survival of patients with intracavitary infec-
tion was 85% at 30 days, 81% at 1 year, and 70% at 2 years.
No surviving patient treated for aortic graft infection with
either conventional management (n = 24) or SFV recon-
struction (n = 7) had aortic stump infection or aorta/graft
aneurysm formation. Recurrent graft infection developed
in 4 (10%) of 40 patients after in situ prosthetic replace-
ment of an aortofemoral graft limb (3 of 25) or extracav-
itary graft (1 of 15), and infection developed in 1 (3%) of
36 patients after autogenous vein replacement (P > .05,
χ2). Secondary procedures, all autogenous vein replace-
ment procedures, isolated P aeruginosa in 1 patient with
urinary conduit, rifampin-resistant S epidermidis strains in
2 patients, and MRSA in 2 patients.
Seventeen (16%) of the surviving 108 patients
required secondary procedures for infection (n = 5), graft
stenosis (n = 6), graft thrombosis (n = 4), bypass for limb
ischemia (n = 1, femoral-femoral SFV bypass graft), or iliac
stent placement for inflow occlusive disease (n = 1). In the
conventional treatment group, four patients had late ex
situ bypass graft thrombosis (n = 3) or infection (n = 1),
resulting in one below-knee amputation after an obturator
bypass graft thrombosis and one below-knee amputation
after recurrent axillofemoral graft thrombosis (Table VI).
Six patients with autogenous vein graft replacement,
including two patients with SFP reconstruction, required
graft revision for stenosis. One patient presented with
graft failure and underwent below-knee amputation after
femoral-peroneal saphenous vein replacement of an
infected femoral-popliteal PTFE bypass graft. Forty-five
(66%) of 68 patients treated for intracavitary and 32 (63%)
of 51 patients treated for extracavitary prosthetic graft
infection experienced no significant in-hospital morbidity
or late complication (recurrent graft infection, secondary
procedure for graft thrombosis/stenosis, limb loss).
DISCUSSION
The clinical spectrum of prosthetic graft infection per-
mits surgeons to individualize treatment and, as docu-
mented in this series, perform in situ replacement in most
patients (52% for intracavitary and 80% for extracavitary
infections). In situ replacement after removal of the entire
infected graft or a graft segment involved by a biofilm
infection was safe (4% [3 of 76 patients] in-hospital mor-
tality rate), durable, and associated with a low (3%) inci-
dence of limb loss (one 3-day and one late amputation).
As in earlier reports, we have found in situ prosthetic
replacement to be appropriate treatment for selected
patients with a localized graft biofilm infection. On the
basis of experimental research that indicated efficacy of a
rifampin-bonded graft in treating low-grade graft infec-
tions, we now use a gelatin–sealed polyester conduit that
has been soaked in a high concentration (60 mg/mL)
solution of rifampin in preference to PTFE to replace
infected graft segments with a “biofilm” infection. In a
recent report, replacement of vascular prosthesis infected
by gram-positive bacteria (S aureus, S epidermidis) with
rifampin-bonded polyester graft was effective in eradicat-
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Table V. Thirty-day or in-hospital operative morbidity and mortality
Treatment group No of patients Mortality (%) Morbidity
Total graft excision alone
Aortoiliofemoral 2 1 None
Extracavitary 7 0 Above-knee amputations (2)
In situ graft replacement
Autogenous conduit
Aortofemoral 10 1 (10) Bowel obstruction (1)
Below-knee amputation (1)
Extracavitary 26 1 (6) Graft thrombectomy (2)
PTFE
Aortoiliofemoral 9 0 Wound infection (1)
Extracavitary* 9 0 Wound infection (2)
Rifampin-bonded
Aortofemoral 16 0 None
Extracavitary 6 1† MRSA infection
Graft excision and ex situ bypass graft
Graft-enteric erosion/fistula 21 6 (29) Chylous ascites (1)
Below-knee amputation (1)
Invasive graft infection
Aortoiliofemoral 10 1 (10) Chylous ascites (2)
Above-knee amputation (2)
Extracavitary 3 0 None
Total 119 11 (9) Amputation (6 [6%])
*All axillofemoral polyester graft infection.
†Patient expired after deep vein replacement of the rifampin-bonded femoral-femoral graft.
ing all clinical signs of infection in 90% of patients.17
Modes of failure after in situ prosthetic replacement
included the development of recurrent infections caused
by a rifampin-resistant S epidermidis strain or persistent
infection in retained aortic graft segments. The morbidity
and late infection rate with the rifampin-bonded graft as a
replacement conduit was similar to prior reports with
PTFE replacement for S epidermidis graft infections, but
in the rifampin-treated group six patients had graft infec-
tion caused by S aureus, including three with
MRSA.7,15,17 Patient outcomes after in situ prosthetic
replacement in this series were similar to the in situ autog-
enous vein reconstruction group despite differences in
microbiology and the extent of graft infection.
The treatment algorithm used in this patient series was
developed to incorporate newer advances in the treatment
of prosthetic graft infections, including staged extra-
anatomic bypass graft in patients with aortic graft infec-
tions, the use of antibiotic-bonded grafts, and autogenous
venous reconstruction with lower-limb deep veins as
described by Clagett and Nevelsteen.2,8,10,15-19 Because
the patient selection criteria used limited in situ replace-
ment treatment to less serious graft infections, the finding
of a higher operative mortality and morbidity in the con-
ventional management and graft excision alone groups
was expected. Although the overall 30-day operative mor-
tality rate was 9% (11 of 119 patients), treatment of a sec-
ondary graft-enteric/fistula was associated with a 28% 
(6 of 21 patients) mortality rate, and graft infection caused
by MRSA was associated with a 30% (3 of 11) mortality
rate, accounting for 75% of the operative deaths. The
higher perioperative mortality rate in the conventional
treatment group (21% [7 of 34 patients]) occurred despite
the use of staged preliminary axillofemoral bypass graft,
when possible, and culture-specific antibiotic administra-
tion. The observation of increased procedural mortality
rates with repair of graft enteric erosion/fistula has been
reported with all treatment options: conventional staged
ex situ bypass graft and total graft excision (19%-25%), 
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in situ prosthetic replacement (13%-30%), deep vein
replacement (12%-20%), and allograft replacement (20%-
40%).1-4,10-12,18,20 Improved outcome in this group of
patients depends, in part, on earlier recognition of the
graft-enteric erosion, thus avoiding emergency procedures
in a septic or hemodynamically unstable patient.
Patients with prosthetic graft infection transferred or
presenting to our referral vascular surgery service had the
clinical presentation of a late-appearing and, in most
instances, a low-grade infectious process. Presenting signs
of sepsis, fever, and bacteremia were limited to patients
with aortoenteric erosion/fistula or extracavitary femoro-
femoral or infrainguinal PTFE infections. In this series,
40% of patients were treated for a biofilm graft infection
caused by S epidermidis strains. In most of these patients,
the biofilm infection involved only a segment(s) of the vas-
cular prosthesis, typically the prosthetic graft limb segment
in the groin or pelvis. In our experience, contrast-enhanced
CT scanning coupled with direct surgical exploration of
unincorporated graft segments for microbiologic sampling
has allowed accurate distinction between a biofilm and an
invasive graft infection because no microorganisms have
been found on Gram stain, and if culture findings were
positive, coagulase-negative bacteria were isolated, thereby,
permitting the “preoperative selection” of a patient for in
situ prosthetic replacement therapy.
If preoperative vascular imaging studies indicated dif-
fuse aortic graft infection or operative exploration indi-
cated the entire prosthesis may be colonized, we preferred
the technique described by Clagett et al8 of using the SFP
venous segment from the lower limbs for reconstruction
of the arterial segment after aortic or femorofemoral graft
excision. Patients must be evaluated to determine if they
are candidates for this procedure. When adequate SFPV
caliber is documented by venous imaging and patients are
sufficiently healthy enough to undergo this procedure, we
think that total prosthetic graft excision and in situ autog-
enous reconstruction is the “best” treatment option for
the patient. In our series of 13 patients, failure of the SFP
Table VI. Late outcome of 108 survivors after conventional, graft excision, or in situ replacement treatment of a pros-
thetic graft infection
In situ replacement
Conventional treatment (27)
Late (>30 d) outcome or graft excision (8) Vein (34) Prosthetic (39)
Death related to graft infection* 0 1 (3%) 1 (3%)
Treatment for recurrent infection 1 (3%) 1 (3%) 4 (10%)
Graft thrombosis 2 (6%) 1 (3%) 1 (3%)†
Graft revision for stenosis 0 6 (17%)‡ 0
Amputation 2 (6%)§ 1 (3%) 0
*One patient died of pneumonia 2 months after deep vein replacement of an aortofemoral graft infection caused by MRSA, and one patient died 3 months
after conventional treatment of an infected retained aortic graft initially treated by graft limb replacement 2 years prior.
†Axillofemoral graft thrombosis successfully treated with thrombectomy and distal anastomotic revision.
‡Saphenous (4) or cephalic (1) vein bypass grafts; one lower-limb deep vein bypass graft required revision for stenosis.
§Below-knee amputation after obturator bypass graft thrombosis and above-knee amputation after recurrent thrombosis of axillofemoral bypass graft.
reconstruction occurred in only one patient with an
MRSA infection, and other morbidity (compartment syn-
drome, acute deep venous thrombosis, limb swelling)
associated with lower limb deep vein excision was minimal
and did not result in any long-term patient disability. We
did encounter several patients who were judged not to be
candidates for neoaortoiliac SFP venous reconstruction
because of prior deep venous thrombosis, small caliber
vein, or medical conditions that precluded a procedure 
of this magnitude. In these instances, if a biofilm graft
infection was present, treatment was either in situ pros-
thetic replacement or conventional management. Of note,
we have not used SFP venous reconstruction to treat 
secondary aortoenteric fistula. In patients with aortic false
aneurysm, bilateral hydronephrosis, or extensive retroperi-
toneal perigraft inflammation, conventional treatment 
was used.
Recurrent graft infection was low in all treatment
groups (conventional management, 3%; in situ vein
replacement, 3%; in situ prosthetic replacement, 10%); the
highest number of infections occurred after in situ pros-
thetic replacement. Recurrent infection was the result of
either progression of a graft biofilm infection in nonex-
cised graft segments or persistent MRSA infection. When
recurrent graft infection was encountered a policy of in
situ autogenous venous reconstruction was followed, 
if feasible. In four patients treated with unilateral aorto-
femoral graft limb replacement, infection of the retained
aortic graft and contralateral limb developed. In these
instances, the prior in situ replaced graft was not infected,
thereby allowing conventional management because one
groin now had no clinical signs of infection and an
axillofemoral prosthetic bypass graft and autogenous
femorofemoral bypass graft could be performed. The low
incidence of axillofemoral graft infection and thrombosis
observed in this series was in part due the patient selection
process. When groin regions were infection free (ie, an
infected aortoiliac bypass graft), conventional manage-
ment was typically selected, and in most patients, the
superficial femoral artery was patent. Aortofemoral graft
infections were primarily treated with autogenous vein or
prosthetic in situ replacement. 
The interest in alternative methods, especially in situ
replacement, to treat prosthetic graft infection is under-
standable. In today’s vascular surgery practice, graft sal-
vage involved by an early (< 3 month) postoperative
infectious process is usually possible if aggressive surgical
wound care is provided, appropriate culture–specific
antibiotic administered, staged debridement procedures
performed, and muscle flap coverage of the exposed graft
used. Similarly for late-appearing graft infections, the
microbiology and anatomic features of the infectious
process permit several options to be considered in an indi-
vidual patient. The goal of therapy for patients presenting
with a prosthetic graft infection is to select a procedure
that first, the patient can tolerate and recover from and
that also eradicates the clinical manifestations and poten-
tial complications of the infectious process. Thus, vascular
surgeons need to be familiar with multiple techniques for
treating prosthetic graft infection, including conventional
management and in situ replacement technique with
SFPV, antibiotic-bonded grafts, and, if available, cryopre-
served allografts. In situ treatment avoids the failure-
prone, extra-anatomic reconstruction, aortic stump
blowout, and increased physiologic stress associated with
multiple or staged procedures. In situ prosthetic replace-
ment is appropriate in properly chosen patients, but
autogenous reconstruction may be superior in reducing
the risk of reinfection.
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DISCUSSION
Dr James M. Seeger (Gainesville, Fla). Dr Bandyk and his col-
leagues are to be congratulated on their results in the manage-
ment of a relatively large number of patients with prosthetic
arterial graft infections and for a nice presentation of their results.
One hundred nineteen patients with various types of infected
grafts were managed using multiple techniques, including con-
ventional treatment for those patients with aortoenteric fistulas,
retroperitoneal sepsis and extensive graft sepsis, and in situ graft
replacement for those who had less severe infections. I certainly
agree with the authors’ conclusion that no one approach is ade-
quate in the treatment of all patients with prosthetic arterial graft
infections. The algorithm presented by Dr Bandyk and his col-
leagues used the degree of graft infection, the patients’ present-
ing symptoms, and their ability to withstand treatment to select
patients for these various treatments, and I would agree that all of
these factors are important selection criteria. Furthermore, the
type of treatment selected for an individual patient with an
infected arterial graft should be based on expected outcomes for
that type of treatment, and the value of this study is to add to our
understanding of those expected outcomes. In contrast, the com-
parisons between groups presented by the authors in this study
are too heavily influenced by their treatment algorithm that used
different approaches in patients with very different potential out-
comes to be of value in choosing between treatment options.
As recent series reviewing outcomes after conventional treat-
ment and in situ autogenous vein graft replacement of infected
arterial grafts have presented results from larger numbers of
patients, I will confine my comments and questions to the
patients in this study who underwent in situ prosthetic graft
replacement for biofilm infections, a particular interest of the
authors. I would, however, note the two patients undergoing in
situ autogenous graft replacement for aortic graft infections who
died of graft disruption, as we have not seen this complication.
Forty patients with limited biofilm graft infections, 25 with intra-
cavitary grafts, and 15 with extracavitary grafts, were treated with
in situ prosthetic graft replacement with a 25% 30-day mortality
rate and a 0% amputation rate. Long-term outcome, with a mean
followup of 18 ± 9 months, demonstrated that 10% of the sur-
viving patients developed clinical signs of recurrent graft infec-
tion, one patient died of graft infection, one had a graft
thrombosis, but no amputations were required. I think these
results, at least in the short term, confirm the authors’ suggestion
that this is a probably acceptable approach to management of
prosthetic graft infection in this very select group of patients.
However, I have several questions for the authors.
1. What happens to patients with biofilm graft infections treated
with in situ prosthetic graft replacement? Is the infection erad-
icated, or do patients treated in this manner merely live in
symbiosis with their infection after placement of a new pros-
thetic graft? If the infection is indolent but still present, what
then is the value of removing the old graft and what would
happen if this type of infection were treated with local meas-
ures, such as irrigation, debridement, and antibiotics alone?
2. Is the use of in situ prosthetic graft replacement for treatment
of arterial graft infection actually expanding? While I agree
with you that Dr Clagett’s work has convinced us to more
commonly use in situ autogenous replacement of infected aor-
tic grafts, at least in our practice, we are not seeing an increas-
ing number of patients who appear to have isolated biofilm
infections appropriate for treatment with in situ prosthetic
graft replacement.
3. If the recurrent infection rate is 10% at 18 months, will the rate
of clinically evident infections continue to increase as time goes
by after in situ prosthetic graft replacement? This goes back to
my first question as to whether infection is truly eliminated or
merely suppressed by this technique. As 70% of patients pre-
senting with arterial graft infection now live for 5 years, will a
significant percentage of these patients be coming back to us
with recurrent and more diffuse infections, and will they then
have to be managed when they are older and less able to toler-
ate a definitive procedure?
I enjoyed your presentation and agree with you that the man-
agement of prosthetic arterial graft infection continues to evolve.
However, I would caution all of us to remember that patients
with arterial graft infections, particularly those with aortic graft
infections, have a complex and life-threatening problem. They
often have only one good shot at achieving both limb salvage and
infection control, which depends on selection of the appropriate
treatment for the patient’s particular type of infection. The intro-
duction of multiple new techniques for managing patients with
this complex problem appears to have improved the outcome for
individual patients with this difficult problem but also has made
the selection of the best treatment for an individual patient more
critical and more difficult.
Dr Michael Novotney. The outcome of patients with biofilm
infections was similar in this series to that reported by Towne and
Bandyk (J Vasc Surg 1994;19:226). All symptoms and signs of
graft infection were eradicated in more than 80% of patients long
term. Graft imaging by ultrasound or computed tomography has
demonstrated residual perigraft fluid involving a segment of the
retained or replaced prosthetic graft in approximately 20% of
patients, and it was in this group that reintervention was required,
usually to treat a biofilm infection of the contralateral
aortofemoral graft limb. Recurrent biofilm of an “in situ”
replaced axillofemoral or femoral-femoral graft did not occur in
this series. The use of “local measures” such as antibiotics and
surgical debridement and muscle flap coverage is usually not suc-
cessful when dealing with a biofilm graft infection. We recom-
mend excision of all involved, unincorporated graft, followed by
either in situ autogenous vein or rifampin-bonded gelatin-
impregnated graft replacement.
As our series documents, a biofilm infection caused by S epi-
dermidis is the most common type of graft infection presenting to
our vascular surgery service. Many of the patients have had pro-
longed administration of antibiotics to resolve a “groin sinus”
often judged initially to not involve the graft, and because of
“negative” cultures, a medical treatment program is prescribed.
When this treatment fails or the groin does not heal after an
attempt at surgical debridement, the patient is referred for defin-
itive treatment.
Recurrence of infection after in situ replacement for a biofilm
infection is typically evident within the first year after prosthetic
graft replacement. No late occurrences after in situ autogenous
replacement have occurred. I agree with Dr Seeger that all
patients with graft infection need to be followed closely. If rein-
fection occurs, treatment should proceed using the same guide-
lines as were used for initial treatment. As indicated in the
presentation, we prefer in situ autogenous replacement for
biofilm graft infections when the patient has appropriate-size
lower-limb deep vein and can medically withstand the procedure.
Dr Spence Taylor (Greenville, SC). It has been interesting;
we have had over the last 3 years three different approaches pre-
sented at this meeting to treat graft infection of which the results
are very similar. Each appears to be an effective treatment,
whether it be extra-anatomic bypass and graft excision or whether
it be an in situ replacement as presented by the South Florida
group. I think it would be interesting to have Dr Clagett and Dr
Seeger and the South Florida group comment. In Greenville we
generally use extra-anatomic bypass as our treatment of choice.
However, I have always been disappointed by the long-term limb
salvage and graft patency. If the infection eradication with the in
situ technique is similar to the extra-anatomic treatment, then
superior late graft patency with in situ technique would be very
attractive. Are limb salvage results and patency better with in situ
in your experience? What is everybody’s feeling in terms of that?
I think that may sway you one way or the other. I would be inter-
ested in your comments. Thanks.
Dr Novotney. As Dr Taylor has alluded to, the results of con-
ventional treatment have also improved during the past several
decades, and excellent vascular surgery groups have continued to
prefer this approach. Dr Seeger and his colleagues at the
University of Florida have shown that the failure rate of axil-
lopopliteal bypass is high and should be avoided. Similarly, the
patency of an axillo-deep femoral bypass that bypasses the com-
mon femoral region is also reduced, especially when the superfi-
cial femoral artery is occluded. Best results occur in patients with
aortic graft infection confined to the abdomen allowing for a pre-
liminary axillofemoral bypass to the common femoral artery. As
indicated in our series, late revision of a lower limb deep vein
bypass was uncommon (1 of 12 grafts). Most revisions for vein
graft stenosis occurred in patients having saphenous or upper
extremity vein bypass to treat an extracavitary graft infection.
Dr Thomas Bergamini (Louisville, Ky). For the recurrent
infections of the in situ prosthetics, what was the distribution
between the rifampin Dacron grafts and the PTFE grafts? Does
the advantage of the ability to bond rifampin to Dacron outweigh
the decreased bacterial adherence of PTFE?
Secondly, you mentioned nothing about the antibiotic regi-
mens. In the orthopedic literature, as I am sure you are aware, the
combination of rifampin with a floxin drug does offer benefit to
clearance of prosthetic adherence bacteria. I am wondering what
your antibiotic regimen was in these patient groups.
Dr Novotney. Intervention for recurrent infection after in situ
PTFE or rifampin-bonded graft replacement was similar. The
application of the rifampin antibiotic-bonded graft has been
expanded to include several patients with S aureus infections,
which became apparent only after obtaining the intraoperative
culture results. Experimentally, our group has documented a
lower reinfection rate when an antibiotic-bonded graft was used,
especially in the setting of an immune-suppressed animal.
Our antibiotic regimen includes vancomycin and a broad-spec-
trum antibiotic(s) begun several days before graft excision if possi-
ble. We try to administer culture-specific antibiotics based on
preoperative or intraoperative graft culture results. Parenteral
antibiotics are administered for at last 6 weeks, and in the case of a
graft biofilm infection consists of vancomycin and oral floxin antibi-
otic. After this time period, an oral fluoroquinolone (ciprofloxacin)
or macrolide (erythromycin, minocycline) is prescribed for an addi-
tional 3 to 4 months. In several patients not felt to be candidates
for total aortic graft excision, we have continued antibiotics.
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